Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grignani

Showing results (641-650 of 688) with videos related to

Pageof 69
Sort By:
Frontiers in Oncology|May 1, 2020
Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working GroupDominga Racanelli, Monica Brenca, Davide Baldazzi, et al.
The Lancet. Oncology|July 24, 2019
Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trialSilvia Stacchiotti, Stefano Ferrari, Andres Redondo, et al.
The Lancet. Oncology|December 23, 2018
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trialJavier Martin-Broto, Silvia Stacchiotti, Antonio Lopez-Pousa, et al.
Cancer Medicine|March 13, 2021
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literatureAnna M Frezza, Vinod Ravi, Salvatore Lo Vullo, et al.
Frontiers in Oncology|July 14, 2020
Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working GroupDominga Racanelli, Monica Brenca, Davide Baldazzi, et al.
The Lancet. Oncology|June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialWilliam D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Tumori|December 9, 2017
EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcomaStefano Ferrari, Stefan S Bielack, Sigbjørn Smeland, et al.
Molecular Cancer Therapeutics|September 23, 2021
Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III TrialJavier Martin-Broto, Maria Lopez-Alvarez, David S Moura, et al.
Critical Reviews in Oncology/Hematology|May 8, 2026
Management of Atypical Cartilaginous Tumors (ACT) An Italian Sarcoma Group Consensus DocumentDomenico A Campanacci, Giacomo Giulio Baldi, Roberto Scanferla, et al.
Cancer|October 13, 2021
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trialSandro Pasquali, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Pageof 69

Showing results (641-650 of 688) with videos related to

Sort By:
Pageof 69
Frontiers in Oncology|May 1, 2020
Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working GroupDominga Racanelli, Monica Brenca, Davide Baldazzi, et al.
The Lancet. Oncology|July 24, 2019
Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trialSilvia Stacchiotti, Stefano Ferrari, Andres Redondo, et al.
The Lancet. Oncology|December 23, 2018
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trialJavier Martin-Broto, Silvia Stacchiotti, Antonio Lopez-Pousa, et al.
Cancer Medicine|March 13, 2021
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literatureAnna M Frezza, Vinod Ravi, Salvatore Lo Vullo, et al.
Frontiers in Oncology|July 14, 2020
Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working GroupDominga Racanelli, Monica Brenca, Davide Baldazzi, et al.
The Lancet. Oncology|June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialWilliam D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Tumori|December 9, 2017
EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcomaStefano Ferrari, Stefan S Bielack, Sigbjørn Smeland, et al.
Molecular Cancer Therapeutics|September 23, 2021
Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III TrialJavier Martin-Broto, Maria Lopez-Alvarez, David S Moura, et al.
Critical Reviews in Oncology/Hematology|May 8, 2026
Management of Atypical Cartilaginous Tumors (ACT) An Italian Sarcoma Group Consensus DocumentDomenico A Campanacci, Giacomo Giulio Baldi, Roberto Scanferla, et al.
Cancer|October 13, 2021
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trialSandro Pasquali, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Pageof 69